| |
Centre for Policy on Ageing | |
 | |
|
| Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil | | Author(s) | Mavis Evans, Andrew Ellis, David Watson |
| Journal title | International Journal of Geriatric Psychiatry, vol 15, no 1, January 2000 |
| Pages | pp 50-53 |
| Keywords | Dementia ; Drugs ; Memory and Reminiscence ; Wirral. |
| Annotation | Donepezil (Aricept), the first widely marketed anticholinesterase inhibitor, has been licensed to treat cognitive losses associated with Alzheimer's disease (AD). There has been controversy over its prescription within the National Health Service (NHS), with different purchasers of health care having different priorities. A protocol was developed and agreed between Clatterbridge Hospital, Bebbington, Wirral and the health authorities; prescribing by consultants commenced in November 1997. 282 patients (ages 44-91) commenced treatment; 47 were withdrawn due to intolerable side-effects or non-compliance. Donepezil treatment showed cognitive improvement in 51% of those who commenced treatment, or 65% of those compliant to 3 months. Cognitive improvement in the selected group of responders was maintained over 12 months. Behavioural improvement is often reported by carers and is sometimes independent of cognitive improvement. Support and counselling of patient and carer is an important component of treatment, and may contribute to the subjective reporting of behavioural improvement. (RH). |
| Accession Number | CPA-000419007 A |
| Classmark | EA: LLD: DB: 84D |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|